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Abstract
Huntington’s disease (HD) is a progressive neurodegenerative illness that affects 2–9/100.000 of the general population. The usual onset is at around age 35–40 years, but there were cases with onset above 55 years. The disease manifests clinically with many neurological and psychiatric symptoms, leading in advanced phases to dementia, but cognitive symptoms are frequently present much earlier in the disease course. HD is caused by an expanded polyglutamine
stretch in the N-terminal part of a 350 kDa protein called huntingtin (HTT). This stretch is encoded by a trinucleotide
CAG repetition in exon 1 of HTT. An expansion of greater than 36 repeats results in HD. The number of repeats is
inversely correlated with the age of onset of motor symptoms, and disease onset during childhood or adolescence is
associated with more than 60 CAG repeats. Mood disturbances may be one of the earliest symptoms of HD and may
precede the onset of the motor pheno-type for almost 10 years. Neuropsychiatric symptoms may delay the appropriate diagnosis of HD and have major implications for disease management, prognosis and quality of life for patients
and families. This case study is about a 58 years old female patient with late identification of Huntington’s disease after
two admissions to psychiatric inpatient units, for the treatment of behavioral disturbances.
Background
Huntington’s disease (HD) is a progressive neurodegenerative illness, which was the first disorder that was
diagnosed using only DNA markers [1]. HD is caused by
an expansion of a trinucleotide (CAG) above 35 repeats
that is inherited in an autosomal dominant manner, with
100 % penetrance when the CAG expansion exceeds 40
repeats and with incomplete penetrance between 36 and
39 repeats [2]. HD affects 2–9/100.000 of the general
population, and has the usual onset at around age 35–40.
It manifests clinically by many neurological and psychiatric symptoms, leading in advanced phases to dementia,
although noticeable cognitive disturbance is frequently
present earlier in the disease [3].
HD is caused by an expanded polyglutamine stretch
in the N-terminal part of a 350 kDa protein called huntingtin (HTT). HTT is ubiquitously expressed and is
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implicated in several cellular functions including control
of transcription, vesicular trafficking, ciliogenesis, and
mitosis. This stretch is encoded by a trinucleotide CAG
repetition in exon 1 of HTT. An expansion of greater
than 39 repeats results in HD [4]. The number of repeats
is inversely correlated with the age of onset of motor
symptoms, and disease onset during childhood or adolescence is associated with more than 60 CAG repeats [5].
Mood disturbances may one of the earliest symptoms of
HD and may precede the onset of the motor phenotype
for almost 10 years [6–8]. The cognitive symptoms have
been shown to be present 15 years prior to the time HD
diagnosis and are related to disease-specific cerebral volume loss [9]. Neuropsychiatric symptoms may delay the
appropriate diagnosis of HD and have major implications
for disease diagnosis, management, prognosis and quality
of life for patients and families [10].
This case study is about a female patient diagnosed
with HD after two admissions to psychiatric inpatient
units, for the treatment of behavioral disturbances. Written informed consent was obtained from the patient for
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publication of this case report and any accompanying
images. A copy of the written consent is available for
review by the Editor-in-Chief of this journal.

Case report
The female patient, 58 years old, was brought to the
psychiatric emergency service and hospitalized for
psychomotor agitation, verbal and physical aggression
towards family, destruction of objects, insomnia, mood
lability, dysphoria, and marked irritability. There were
no signs of hallucinations, delusions or formal though
disorder, the patient denied suicidal ideas. Psychotic or
mood disorder diagnoses were excluded. The general
physical examination revealed choreiform movements
of the upper and lower limbs and head with gait and
speech disturbances. The patient’s family declared that
these disturbances started 2 years ago, but the patient
neglected them. The patient smoked 20 cigarettes/day,
but did not use alcohol or any other psychoactive substance. The patient’s father died at the age of 61 after
acute renal failure. The mother died at age of 70 after a
cerebral stroke. The patient stated that before her mother’s death she presented some abnormal movements of
hands and head, but without any neurological examination. The patient’s daughter was advised to perform the
genetic test, but she did not follow this recommendation at the time.
Her family reported that 12 months ago the patient had
a short episode of loss of consciousness, without seizures,
from which she spontaneously recovered and which was
not investigated at all. Two years ago, the patient was
hospitalized at another psychiatric unit for similar behavioral symptoms considered at that time as an adjustment
disorder. The neurological examination did not reveal
pathological findings at that time. Thereafter, she was
treated as an outpatient for mood symptoms that were
considered to be part of a personality disorder.
Investigations
The routine admission blood work, including electrolytes, renal, hepatic and thyroid parameters as well as
full blood count with differential, were all within normal
limits. The neurological evaluation found high amplitude
choreiform involuntary movements, dysarthria, mild
bilateral ataxia, normal sensory and power examination, normal reflexes and mild cognitive impairment (27
points on Mini Mental State Examination). The hospital
protocol for psychological evaluation included beyond
the MMSE the Raven Standard Progressive matrices for
intelligence coefficient (IQ) and Wechsler’s Deterioration
Index. The results were normal (IQ = 98 and a deterioration index less than 4 %). The EEG was normal, but the
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CT scan (without contrast) showed marked, predominantly frontal cortical atrophy, large sylvian valleys and
increased size of the ventricular system.
Based on the clinical symptoms, a degenerative illness,
such as Huntington’s disease, was suspected. Genetic
testing for the HTT gene was performed for confirmation and was analyzed by PCR amplification with specific primers, followed by capillary electrophoresis. For
one allele, 43 CAG repeats were detected, and the second
allele had 10 CAG repeats. Considering that presence of
more than 39 CAG repeats is considered pathological,
the conclusion of the genetic analysis was that the patient
either already had Huntington’s disease or would develop
it in the future.
After the genetic test results had been obtained, the
patient was re-evaluated by the neurologist, who established the definite diagnosis of Huntington’s disease,
confirmed both on clinical and genetic grounds. She is
currently treated with small doses of haloperidol (1 mg/
day) and clonazepam (2 mg/day) with good results
regarding behavioral and movement symptoms.

Discussion
This case report is about a patient with late identification of HD at age 58 in a female who was diagnosed for
the first time during her second psychiatric hospitalization for psychomotor agitation, aggression, and irritability. The presence of choreiform movements prompted
the genetic testing, which together with the clinical picture led to the definite diagnosis of HD, but her diagnosis was delayed by prominence of neuropsychiatric
symptomatology.
The particularity of this case is the delayed diagnosis
of HD due to psychiatric symptoms and relatively late
onset of the illness, based on the history of first emerging abnormal involuntary movements after the age of 55,
although the literature usually mentions that the most
frequent age of onset is 35–40 years [11].
The onset of the illness was correlated with the beginning of functional impairment, both professionally (she
was early retired at age of 56) and socially (she and her
husband divorced). The patient was not much aware of
or impaired by the abnormal movements and she did not
seek medical consultation, as she considered it to be “a
nervous tic”. However, the symptom that required medical attention, mostly at her family’s repeated requests,
was the behavioral disinhibition. Often, people with
HD may show reduced awareness of physical and mental changes in themselves [12]. The lack of awareness
was also seen in this patient and is an important corollary of HD that contributes to delays in help-seeking and
reporting of newly emerging problems, further delaying
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the clinical diagnosis and treatment of HD. In our case,
although the CT scan showed relevant cortical atrophy,
the cognitive impairment was mild, without presence of
clinical criteria for a dementia diagnosis. The patient’s
psychiatric abnormalities, mainly the behavioral disinhibition, irritability and aggression were likely correlated
with the predominantly frontal cortical atrophy. Given
the comparatively late onset of HD, the low abnormal
number of CAG repeats and mild cognitive dysfunction,
it is reasonable to assume that the affected parent in this
case was the patient’s mother who had been diagnosed
with “cerebral circulatory insufficiency” [13]. Available
data suggest that there is a tendency for the affected
descendant to present a larger CAG repeat expansion,
which is believed to be responsible for a more malignant
course of the disease. While gene transmission from the
father has been associated with a higher risk for the rigidakinetic type of HD with childhood onset [14], in women
there is an equal risk of contraction or expansion of the
CAG repeat [15].
There have been several studies showing that psychiatric symptoms may precede motor symptoms and the
ultimate diagnosis of HD [16, 17]. However, in this case,
abnormal movements seem to have preceded the psychiatric disturbances by at least 1 year, but it was the latter
that led to clinical attention and ultimate diagnosis at
least 2 years after the onset of the abnormal movements.
This case also illustrates the need to educate psychiatric care providers in recognizing potential neurological
reasons for psychiatric presentations, as HD had been
missed during the first hospitalization 1 year ago. A suspicion of HD requires the physician to request a genetic
test for diagnostic confirmation and, in case of a definite
diagnosis, to refer the patient for genetic consultation
and counseling, considering that HD is currently incurable and that the descendants of affected parents have a
50 % chance to inherit the disease [18].

Conclusions
Huntington’s disease is a rare condition which is frequently underdiagnosed, especially early on in the disease. This situation is caused by lack of recognition of
HD symptoms, which are often attributed to another
disease by patients, family members and sometimes even
physicians.
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